Raymond James Financial
ZNTL icon

Raymond James Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Raymond James Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.6K Buy
22,895
+3,000
+15% +$7.75K ﹤0.01% 5119
2025
Q4 		$26.9K Sell
19,895
-700
-3% -$1.02K ﹤0.01% 5065
2025
Q3 		$31.1K Hold
20,595
– – ﹤0.01% 4871
2025
Q2 		$23.9K Sell
20,595
-1,670
-8% -$2.2K ﹤0.01% 5528
2025
Q1 		$35.4K Sell
22,265
-175
-0.8% -$377 ﹤0.01% 4669
2024
Q4 		$68K Buy
+22,440
New +$73.5K ﹤0.01% 4568

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Raymond James Financial's ZNTL Position: Q1 2026 in Review

Raymond James Financial increased its Zentalis Pharmaceuticals (ZNTL) stake by 15% in Q1 2026, buying an estimated $7.75K and bringing the position to 22,895 shares worth $53.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5119.

Raymond James Financial first reported a position in ZNTL in Q4 2024 and has held it in 6 quarters since. The position peaked at $68K in Q4 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Raymond James Financial held 22,895 shares of Zentalis Pharmaceuticals worth $53.6K as of Q1 2026.
  • Raymond James Financial bought 3,000 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $7.75K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5119 holding.
  • Raymond James Financial first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Zentalis Pharmaceuticals position peaked at $68K in Q4 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.